SUPN
Supernus
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 0
Sell signal 3
Net Income Plunges
EPS Below Expectations
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About SUPN
Supernus Pharmaceuticals, Inc.
A biopharmaceutical company that focused products for the treatment of central nervous system diseases
9715 Key West Avenue
, Rockville
, MD 20850
--
Supernus Pharmaceuticals, Inc., was incorporated in Delaware on March 30, 2005 and commenced operations on December 22, 2005. The Company is a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system diseases. The company's diverse neuroscience portfolio includes approved treatments for attention deficit hyperactivity disorder, dyskinesia in Parkinson's disease patients treated with levodopa, low activity in PD, epilepsy, migraine, cervical dystonia and chronic saliva flow. The company is developing a broad range of novel CNS product candidates, including new potential therapies for the treatment of epilepsy, depression and other CNS disorders.
Earnings Call
Q1/2025
Estimate EPS0.37
Actual EPS-0.21
Estimate Revenue147.94M
Actual Revenue149.82M
Supernus Pharmaceuticals' Q1 2025: Unpacking Contradictions on Qelbree Growth, SPN-820 Strategy, and Reimbursement Challenges
May 07,2025 07:28
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
SUPN has released its 2025 Q1 earnings. EPS was reported at -0.21, versus the expected 0.37, missing expectations. The chart below visualizes how SUPN has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
SUPN has released its 2025 Q1 earnings report, with revenue of 149.82M, reflecting a YoY change of 4.30%, and net profit of -11.83M, showing a YoY change of -9637.90%. The Sankey diagram below clearly presents SUPN's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
